ASCRS completes second annual Clinical Survey; develops educational gaps to address in 2015

More than 1,500 members provided information on clinical opinions and practice patterns to drive the future of ASCRS education

Survey overview

The second annual ASCRS Clinical Survey was performed both at the ASCRS•ASOA Symposium & Congress in Boston and via electronic follow-up surveys to the ASCRS membership. More than 1,500 physicians responded to this survey, which included 134 questions that created 267 unique measurable data elements. Survey questions were developed and reviewed with the ASCRS Clinical Committees and validated by a social science statistician. 50.2% of the respondents were from the United States, while 49.8% were from outside the United States. Additionally, 17% of respondents were young ophthalmologists, either a resident, fellow, or within 5 years of practice, who were asked another set of questions on their experiences to date.

The survey asked ASCRS members key questions relating to current issues they face on a regular basis. With more than 1,500 responses, a significant percentage of the membership was represented and the results were reviewed and interpreted by the ASCRS Clinical Committees. Proficiencies and deficiencies were assessed to develop educational objectives and gaps for future ASCRS programming.

Cataract & LVC Surgery: Overall Procedures

- Average cataract annual volume: 490
  - Toric IOLs: 8.4%
  - Presbyopia-correcting IOL: 7.2%
- Average LVC annual volume: 290

Cataract & LVC Surgery: Overall Procedures

- 83.7% of U.S. respondents are very or extremely concerned about the future of Medicare in their practice
- 63%: overall practice revenue split, between Medicare/Insurance reimbursement vs. Elective (private pay) revenue

Respondent Demographics: Gender

<table>
<thead>
<tr>
<th>Practicing</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resident/Fellow</td>
<td>59.5%</td>
<td>40.5%</td>
</tr>
<tr>
<td>0–5 years</td>
<td>60.1%</td>
<td>39.9%</td>
</tr>
<tr>
<td>6–10 years</td>
<td>69.2%</td>
<td>30.8%</td>
</tr>
<tr>
<td>11–20 years</td>
<td>79.6%</td>
<td>20.4%</td>
</tr>
<tr>
<td>21–30 years</td>
<td>82.6%</td>
<td>17.4%</td>
</tr>
<tr>
<td>More than 30 years</td>
<td>92.3%</td>
<td>7.7%</td>
</tr>
</tbody>
</table>

While many surveys provide important data for our profession, most are not used to drive specific educational efforts aimed at improving the practice of medicine and assessing key clinical opinions. This is the objective behind the annual ASCRS Clinical Survey.

In addition to this exclusive overview supplement, please watch for articles in upcoming issues of EyeWorld and JCRS that will feature important detailed analysis of this data and commentary on key trends and gaps highlighted in the coming pages.
Presbyopia Correction

Many physicians are implanting presbyopia-correcting IOLs, however, often patients have increased expectations for a full range of vision post cataract surgery. Several clinical and practice barriers must be overcome for successful implementation and optimal patient outcomes.

44% of ASCRS members believe that 0.75 D or more of residual cylinder does not have a significant impact on visual quality. However, 42% of ASCRS members responded that they do not use LVC to correct this error.

ASCRS members demonstrated that, on average, presbyopia-correcting IOL patients were less satisfied with intermediate vision versus near and distance vision.

Although cost to the patient was stated as the biggest barrier to converting more patients to presbyopia-correcting IOLs, 40% of members believe that more than 5% of these patients have significant dysphotopsia.
ASCRS leadership has identified several educational gaps pertaining to pre-, intra-, and postoperative management of toric IOL patients.

More than 30% of respondents to the 2014 ASCRS Clinical Survey reported that 10 degrees or more of postoperative rotational error is acceptable with a toric IOL before visual quality and acuity are significantly affected.

More than 37% of respondents are using anatomical landmarks or ink marking without the aid of axial instruments.

Although topography is the most common measurement that drives astigmatism axis decisions when implanting a toric IOL, there is otherwise little consistency on diagnostic devices.
The Refractive Ocular Surface

While the newest diagnostics and devices are most common to focus on for improved visual outcomes, the impact of a healthy ocular surface is often underestimated. There is a need to focus on the impact of the ocular surface, pertaining to its impact on cataract and refractive outcomes and patient satisfaction.

ASCRS members see an average of 34 patients per month that are on dry eye therapies or have punctal occlusion. However, when asked about the Delphi/DEWS guidelines for treating aqueous deficient dry eye and MGD, more than 1/3 of respondents were unaware of the recommended protocols.

Approximately 1/5 of all cataract and refractive patients present to ASCRS members with sufficient ocular surface dysfunction to require advanced therapies.

Even with the launch of advanced tear film diagnostics, more than 60% of ASCRS members still strongly agree or agree that Schirmer’s testing reliably increases diagnostic accuracy, while only 13% currently believe that advanced tear diagnostics should be implemented at the point of care.

40.5% of members strongly agree that mild/moderate OSD impacts outcomes

62% of ASCRS members still strongly agree or agree that Schirmer’s testing reliably increases their diagnostic accuracy.
Laser-Assisted Cataract Surgery

Laser-assisted cataract surgery (LACS) is a rapidly evolving category, with new technology iterations launching and frequent clinical data updates.

Reimbursement strategies and access to LACS technology is still a significant hurdle for many ASCRS members, with almost 1/3 of respondents not yet able to gain access.

More than 50% of respondents reported seeing no clinical benefits vs. conventional cataract surgery for capsulorhexis creation, lens fragmentation, and arcuate incisions.

Respondents to the 2014 ASCRS Clinical Survey are optimistic about the future of LACS, with almost 92% stating they will be performing LACS at some level in 10 years.
**Young Physicians: Premium Technology**

Residents, fellows, and ophthalmologists within 5 years of practice were 17% of the overall respondents to the 2014 ASCRS Clinical Survey. This group showed a strong desire to have greater education with advanced cataract and refractive technologies.

<table>
<thead>
<tr>
<th>Data Supporting Gap</th>
<th>Young Physicians: Premium Technology Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase understanding and exposure of young physicians to advanced refractive cataract and laser vision correction technology</td>
<td></td>
</tr>
<tr>
<td>- Exposure to advanced technology IOLs, laser cataract surgery and corneal refractive technology</td>
<td></td>
</tr>
</tbody>
</table>

In addition to low toric and presbyopia-correction IOL implantation, a significant percentage of young ophthalmologists stated they had inadequate experience with these technologies during residency.

Almost 2/3 of all young ophthalmologist ASCRS members had no formal refractive curriculum training in residency.

<table>
<thead>
<tr>
<th>Data Supporting Gap</th>
<th>Young Physicians: Premium Technology Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>63.1% had no formal refractive curriculum training</td>
<td></td>
</tr>
<tr>
<td>- Majority believe residency is the appropriate time to start training of these technologies</td>
<td></td>
</tr>
</tbody>
</table>

Similar to advanced-technology IOL experience, 68.8% of young ophthalmologist respondents believed they had inadequate exposure to laser vision correction technology in residency.

<table>
<thead>
<tr>
<th>Data Supporting Gap</th>
<th>Young Physicians: Premium Technology Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>68.3% had performed 5 or less laser vision correction procedures</td>
<td></td>
</tr>
</tbody>
</table>

![Chart showing how many laser vision correction procedures residents performed during residency](chart.png)
Post-Cataract Surgery Inflammation

Inflammation plays an integral role in patient satisfaction, outcomes, and overall surgical success. Modern therapies and patient expectations help doctors progress toward the minimization, and eventual elimination, of post-cataract surgery inflammation.

More than 1/3 of ASCRS members expect 1+ cell/flare as a normal level of inflammation 3–7 days after cataract surgery. Additionally, 40.2% are using BOTH NSAIDs and steroids at 1 day postop.

Laser Vision Correction

Advanced diagnostics and newer ablation profiles have routinely driven outcomes to exceed 20/20 UCVA once used as a successful measurement. New data has also demonstrated there may be a gap in the perceived and true incidence of dry eye and ectasia rates with LASIK.

The large majority of respondents use 20/20 UCVA or have no standardized way of assessing a successful laser vision correction procedure. Additionally, respondents believe that LASIK has increased dry eye in 32% of patients, and 1/3 routinely use the Randleman criteria to determine LASIK vs. PRK candidacy.
Managing the Diabetic Cataract Patient

The 2014 ASCRS Clinical Survey set out to determine the educational needs for anterior segment surgeons pertaining to managing the diabetic cataract patient. The data demonstrates a high patient base among members, as well as an educational gap on treatments.

In addition to intravitreal injections, 9.4% of patients are simultaneously actively managed for AMD, and 8.1% of patients are simultaneously actively managed for DME. However, 35.8% of ASCRS members do not believe they have an in-depth understanding of these therapies and their impact.

Advanced Glaucoma Treatments

ASCRS members see an average of 470 glaucoma patients annually. U.S. physicians see more glaucoma patients on average versus O-U.S. physicians. Overall, 53% of cataract patients are getting a PGA for long-term IOP management.

Overall, ASCRS members reported that 8.6% of their cataract patients are also candidates for microincision glaucoma surgery (MIGS). While 16.2% of members currently offer MIGS, more than ¼ will be offering the procedure within 12 months.